Diadema Partners’s TG Therapeutics TGTX Stock Holding History

Diadema Partners’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.16M	Buy	+75,700	New	+$3.1M	0.53%	50

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Diadema Partners's TGTX Position: Q2 2026 in Review

Diadema Partners sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 206,928 shares — an estimated $8.47M sold.

Diadema Partners first reported a position in TGTX in Q4 2024 and held it in 6 quarters. The position peaked at $13.4M in Q2 2025. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Diadema Partners reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
Diadema Partners sold 206,928 TG Therapeutics shares in Q2 2026, an estimated $8.47M.
Diadema Partners first reported a position in TG Therapeutics in Q4 2024 and held it in 6 quarters.
Diadema Partners's TG Therapeutics position peaked at $13.4M in Q2 2025.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.